Fig. 4: Clinical safety of RBI-4000. | Nature Communications

Fig. 4: Clinical safety of RBI-4000.

From: Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

Fig. 4

A Local solicited and B Systemic solicited adverse reactions following 1 and 2 doses of RBI-4000 and RabAvert. Cohort 3 only received a single dose of RBI-4000. Maximum severity of each symptom is plotted. Reactogenicity was described as grade 1 (blue), grade 2 (green), or grade 3 (yellow).

Back to article page